19 unknown. 19 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Unknown 19 |
| Phase 2 | 6 | Unknown 6 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease Nilotinib BE 84mg, Nilotinib BE 112 mg, Placebo - Alzheimer Disease | Phase 3 | Unknown | KeifeRx, LLC | 1275 | 2022-02-01 | 2021-12-03 |
| A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease PM012, PM012 Placebo, Donepezil - Mild Alzheimer Disease | Phase 2 / Phase 3 | Unknown | Mediforum Ltd., Co. | 312 | 2020-11-27 | 2023-04-18 |
| Multimodal Biomarkers for Diagnosis and Prognosis in VCI amyloid PET - Vascular Cognitive Impairment, Alzheimer Disease | Phase 3 | Unknown | National Taiwan University Hospital | 120 | 2020-09-03 | 2020-10-27 |
| Noradrenergic Add-on Therapy With Guanfacine Guanfacine, Placebo - Alzheimer Disease | Phase 3 | Unknown | Imperial College London | 148 | 2019-01-04 | 2024-05-13 |
| Multimodal Biomarkers for Diagnosis and Prognosis in CAA 1. amyloid PET；2. T807 PET - Cerebral Amyloid Angiopathy, Intracranial Hemorrhages | Phase 3 | Unknown | National Taiwan University Hospital | 240 | 2018-09-27 | 2021-03-12 |
| 18F-Flutemetamol and Plaque Vulnerability 18F-Flutemetamol PET/MRI - Atherosclerosis | Phase 2 / Phase 3 | Unknown | Maastricht University Medical Center | 25 | 2018-02-01 | 2019-07-11 |
| Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease Octohydroaminoacridine Succinate, Aricept, Placebos - Alzheimer Disease | Phase 3 | Unknown | Shanghai Mental Health Center | 600 | 2017-08-16 | 2019-10-22 |
| Neurostimulation and Cognitive Intervention in Alzheimer's Disease active tDCS, sham tDCS, real CT - Alzheimer's Disease | Phase 2 / Phase 3 | Unknown | Federal University of Paraíba | 60 | 2016-05-01 | 2016-05-13 |
| Zydena on Cognitive Function of Alzheimer's Disease Patients Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg, Placebo + Donepezil 5mg or 10mg, Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg - Alzheimer's Disease | Phase 3 | Unknown | Samsung Medical Center | 210 | 2013-09-01 | 2013-09-12 |
| A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology [18F]NAV4694 - Dementia, Alzheimer's Disease | Phase 3 | Unknown | Navidea Biopharmaceuticals | 290 | 2013-06-01 | 2017-07-26 |
| Mirtazapine for Sleep Disorders in Alzheimer's Disease Mirtazapine - Alzheimer's Disease, Sleep Disorders | Phase 3 | Unknown | Brasilia University Hospital | 30 | 2012-05-01 | 2013-06-04 |
| Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease Huperzine A, huperzine A, Placebo - Alzheimer's Disease | Phase 2 / Phase 3 | Unknown | Shandong Luye Pharmaceutical Co., Ltd. | 390 | 2010-05-01 | 2011-01-25 |
| Thalidomide for Patients With Mild to Moderate Alzheimer's Disease Thalidomide - Alzheimer's Disease | Phase 2 / Phase 3 | Unknown | Banner Health | 20 | 2010-03-01 | 2012-08-08 |
| A Pilot Study of Inflammatory Markers in Alzheimer's Disease doxycycline, rifampin, placebo - Alzheimer's Disease | Phase 3 | Unknown | McMaster University | 21 | 2008-05-01 | 2009-02-04 |
| Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Music Therapy - Dementia, Alzheimer's Disease | Phase 2 / Phase 3 | Unknown | National Ageing Research Institute, Australia | 180 | 2007-03-01 | 2007-03-16 |
| Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease Tramiprosate (3APS) - Alzheimer's Disease | Phase 3 | Unknown | Bellus Health Inc. - a GSK company | 650 | 2006-05-01 | 2007-07-16 |
| European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients 3APS - Alzheimer's Disease | Phase 3 | Unknown | Bellus Health Inc. - a GSK company | 930 | 2005-09-01 | 2007-12-10 |
| Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease 3APS - Alzheimer Disease | Phase 3 | Unknown | Bellus Health Inc. - a GSK company | 950 | 2004-06-01 | 2007-02-28 |
| Vitamin E in Aging Persons With Down Syndrome Vitamin E, multivitamin, Placebo - Down Syndrome, Alzheimer Disease | Phase 3 | Unknown | New York State Institute for Basic Research | 350 | 2002-04-01 | 2012-05-04 |
Alzheimer Disease (19) · Dementia (5) · Atherosclerosis (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cerebral Amyloid Angiopathy (1) · Cerebral Hemorrhage (1) · Dementia, Vascular (1) · Down Syndrome (1) · Inflammation (1) · Intracranial Hemorrhages (1) · Lewy Body Disease (1) · Nervous System Diseases (1) · Sleep Initiation and Maintenance Disorders (1) · Sleep Wake Disorders (1)
Mental Disorders (19) · Neurocognitive Disorders (19) · Neurodegenerative Diseases (19) · Brain Diseases (18) · Central Nervous System Diseases (18) · Nervous System Diseases (18) · Dementia (14) · Cardiovascular Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Vascular Diseases (3) · Arterial Occlusive Diseases (2) · Arteriosclerosis (2) · Cerebrovascular Disorders (2) · Intracranial Arterial Diseases (2)
Donepezil (3) · Doxycycline (1) · Geritol (1) · Guanfacine (1) · Mirtazapine (1) · Music Therapy (1) · Rifampin (1) · Thalidomide (1) · Tocopherols (1) · Vitamin E (1) · huperzine A (1) · tramiprosate (1) · udenafil (1)
Bellus Health Inc. - a GSK company (3) · National Taiwan University Hospital (2) · Banner Health (1) · Brasilia University Hospital (1) · Federal University of Paraíba (1) · Imperial College London (1) · KeifeRx, LLC (1) · Maastricht University Medical Center (1) · McMaster University (1) · Mediforum Ltd., Co. (1) · National Ageing Research Institute, Australia (1) · Navidea Biopharmaceuticals (1) · New York State Institute for Basic Research (1) · Samsung Medical Center (1) · Shandong Luye Pharmaceutical Co., Ltd. (1)
United States (5) · Canada (3) · United Kingdom (3) · Australia (2) · Brazil (2) · China (2) · Netherlands (2) · South Korea (2) · Taiwan (2) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Spain (1)
Arthur J Dalton, PhD (1) · Brandon M Kucher, PhD, MD (1) · Carolyn Liebsack, BSN (1) · Cornelia Reininger, MD PhD (1) · D.William Molloy, MB, MRCPI, FRCPC (1) · Francisca M Scoralick, MD (1) · Jonathan B Barber, PhD (1) · Mary C Sano, PhD (1) · Michel P Rathbone, MB, PhD (1) · Paresh Malhotra, MA BMBCh PhD (1) · Paul S Aisen, MD (1) · Pr. Bruno Vellas (1) · Shifu Xiao, M.D., Ph.D. (1) · Shucui Jiang, MD,PhD (1)
PMID 30450044, PMID 33189083, PMID 33883015, PMID 35915506, PMID 37859768, PMID 40049590, PMID 42032764
R01AG016381 (1)